Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence
Reexamination Certificate
2006-08-08
2011-11-08
Harris, Alana M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
8 to 10 amino acid residues in defined sequence
C530S300000, C424S009100, C424S009200, C424S184100, C424S185100, C436S064000, C436S086000, C514S001100, C514S019200, C514S019300
Reexamination Certificate
active
08053556
ABSTRACT:
It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B):(A) a peptide, which has the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or(B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells.
REFERENCES:
patent: 7303914 (2007-12-01), Wang et al.
patent: 2004/0253606 (2004-12-01), Aziz et al.
patent: 2008/0044818 (2008-02-01), Nishimura et al.
patent: 01/47944 (2001-07-01), None
patent: 2004/018667 (2004-03-01), None
patent: 2004/022739 (2004-03-01), None
patent: 2004/038420 (2004-05-01), None
patent: 2005/039380 (2005-05-01), None
Greenspan et al. Nature Biotechnology 17: 936 and 937, 1999.
Blythe et al. Protein Science. 14: 246-248, 2005.
Chamberlain et al. Expert Opinion on Pharmacotherapy 1(4): 603-614, 2000.
Bodey et al. Anticancer Research 20: 2665-2676, 2000.
Gura et al. Science 278: 1041 and 1042, Nov. 7, 1997.
Australian Office Action that issued with respect to patent family member Australian Patent Application No. 2006277295, dated Jan. 31, 2011.
Parker et al., “Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains,”J. Immunol.152(1):163-175 (1994).
Nakatsura et al., “Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker”Biochem. Biophys. Res. Commun.306:16-25 (2003).
Nakatsura et al., “Identification of Glypican-3 as a Novel Tumor Marker for Melanoma”Clin. Cancer Res.10:6612-6621 (2004).
Köhler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity”Nature256:495-497 (1975).
Takahashi et al., “Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs”Nature344:873-875 (1990).
Mouritsen et al., “pH Dependence of the Interaction Between Immunogenic Peptides and MHC Class II Molecules”J. Immunol.148(5):1438-1444 (1992).
Nakatsura et al., “Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method”Eur. J. Immunol.32:826-836 (2002).
Monji et al., “Identification of Novel Human Cancer/Testis Antigen, KM-HN-1, Recognized by Cellular and Humoral Immune Responses”Clin. Cancer Res.10:6047-6057 (2004).
U.S. Appl. No. 11/577,435 (Nishimura et al.), filed Apr. 18, 2007 and entitled “Novel Diagnostic Kit for Malignant Melanoma”.
H. Komori et al., “Identification of HLA-A2- or HLA-A24-Restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular Carcinoma,”Clin. Cancer Research,vol. 12, No. 9, pp. 2689-2697 (2006).
Y. Motomura et al., “HLA-A2 and -A24-Restricted Glypican-3-Derived Peptide Vaccine Induces Specific CTLs: Preclinical Study Using Mice,”International Journal of Oncology,vol. 32, pp. 985-990 (2008).
Nukaya et al., “Identification of HLA-A24 Epitope Peptides of Carcinoembryonic Antigen Which Induce Tumor-Reactive Cytotoxic T Lymphocytes”Int. J. Cancer80(1):92-97, 1999.
Pilia et al., “Mutations in GPC3, a Glypican Gene, Cause the Simpson-Golabi-Behmel Overgrowth Syndrome”Nature Genetics12(3):241-47, 1996.
Zhu et al., “Enhanced Glypican-3 Expression Differentiates the Majority of Hepatocellular Carcinomas from Benign Hepatic Disorders”Gut48(4):558-64, 2001.
Nakatsura et al., Proceedings Sixty-First Annual Meeting of the Japanese Cancer Association, vol. 93 Supplement, p. 378, 1338 “Glypican-3, overexpressed specifically in human hepatocellular carcinoma, may prove to be novel tumor marker and potential candidate for immunotherapy” (2002), along with an English language translation.
Komori Hiroyuki
Nakatsura Tetsuya
Nishimura Yasuharu
Greenblum & Bernstein P.L.C.
Harris Alana M.
Oncotherapy Science, Inc.
LandOfFree
Glypican-3 (GPC3)-derived tumor rejection antigenic peptides... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glypican-3 (GPC3)-derived tumor rejection antigenic peptides..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glypican-3 (GPC3)-derived tumor rejection antigenic peptides... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4284383